EE361 Cost-Effectiveness Analysis of Ribociclib Versus Abemaciclib in the First-Line (1L) Treatment of Postmenopausal Women With HR+/HER2- Advanced Breast Cancer (ABC)
| Autor: | Cameron, D, Sharma, V, Biswas, C, Clarke, C, Chandiwana, D, Pathak, P |
|---|---|
| Zdroj: | In Value in Health December 2022 25(12) Supplement:S126-S126 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect